AU2020341114A1 - Novel method - Google Patents

Novel method Download PDF

Info

Publication number
AU2020341114A1
AU2020341114A1 AU2020341114A AU2020341114A AU2020341114A1 AU 2020341114 A1 AU2020341114 A1 AU 2020341114A1 AU 2020341114 A AU2020341114 A AU 2020341114A AU 2020341114 A AU2020341114 A AU 2020341114A AU 2020341114 A1 AU2020341114 A1 AU 2020341114A1
Authority
AU
Australia
Prior art keywords
tissue
organ
cells
brain
regulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020341114A
Other languages
English (en)
Inventor
James Dooley
Matthew Holt
Adrian LISTON
Emanuela PASCIUTO
Lydia YSHII
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Babraham Institute
Original Assignee
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Babraham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven, Vlaams Instituut voor Biotechnologie VIB, Babraham Institute filed Critical Katholieke Universiteit Leuven
Publication of AU2020341114A1 publication Critical patent/AU2020341114A1/en
Assigned to VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, BABRAHAM INSTITUTE reassignment VIB VZW Amend patent request/document other than specification (104) Assignors: BABRAHAM INSTITUTE, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D, VIB VZW
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020341114A 2019-09-06 2020-09-07 Novel method Pending AU2020341114A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1912863.6A GB201912863D0 (en) 2019-09-06 2019-09-06 Novel method
GB1912863.6 2019-09-06
PCT/GB2020/052148 WO2021044175A1 (en) 2019-09-06 2020-09-07 Novel method

Publications (1)

Publication Number Publication Date
AU2020341114A1 true AU2020341114A1 (en) 2022-03-31

Family

ID=68241092

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020341114A Pending AU2020341114A1 (en) 2019-09-06 2020-09-07 Novel method

Country Status (9)

Country Link
US (1) US20220220180A1 (https=)
EP (1) EP4025226A1 (https=)
JP (1) JP7737979B2 (https=)
KR (1) KR20230035210A (https=)
CN (1) CN115397441A (https=)
AU (1) AU2020341114A1 (https=)
CA (1) CA3153063A1 (https=)
GB (1) GB201912863D0 (https=)
WO (1) WO2021044175A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL307633A (en) * 2021-04-12 2023-12-01 Univ Pennsylvania Useful preparations in the treatment of spinal muscular atrophy (SBMA)
GB202118073D0 (en) 2021-12-14 2022-01-26 Babraham Inst Novel method and composition comprising IL-2 and a tissue- or organ-specific targeting moiety
GB202202628D0 (en) 2022-02-25 2022-04-13 Babraham Inst Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017060510A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of alzheimer's disease
KR102423442B1 (ko) * 2015-12-11 2022-07-20 캘리포니아 인스티튜트 오브 테크놀로지 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드

Also Published As

Publication number Publication date
JP2022548217A (ja) 2022-11-17
JP7737979B2 (ja) 2025-09-11
CN115397441A (zh) 2022-11-25
CA3153063A1 (en) 2021-03-11
EP4025226A1 (en) 2022-07-13
KR20230035210A (ko) 2023-03-13
GB201912863D0 (en) 2019-10-23
US20220220180A1 (en) 2022-07-14
WO2021044175A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
US20220220180A1 (en) Novel method
Mowat et al. Gene therapy in a large animal model of PDE6A-retinitis pigmentosa
JP6684343B2 (ja) ニューロン生存因子の相乗組み合わせ及びその使用
JP2010509235A (ja) 多発性硬化症の治療
JP2016538276A (ja) 筋萎縮性側索硬化症の処置のためのＮＦ−κＢおよびＳＯＤ−１を阻害する組成物および方法
Hsu et al. Subretinal gene therapy delays vision loss in a Bardet-Biedl Syndrome type 10 mouse model
Hellström et al. Negative impact of rAAV2 mediated expression of SOCS3 on the regeneration of adult retinal ganglion cell axons
US20220347321A1 (en) Expression of neuropeptides
US12496356B2 (en) Neuroprotection of neuronal soma and axon by modulating ER stress/UPR molecules
Abdullah et al. Targeted deletion of T‐cell S1P receptor 1 ameliorates cardiac fibrosis in streptozotocin‐induced diabetic mice
JP2021525531A (ja) 優性網膜色素変性症の処置のための組成物および方法
KR20250020536A (ko) 타우 단백질 집적 억제용 조성물 및 집적억제 방법
US12491223B2 (en) Method for treating an auditory neuropathy spectrum disorder
EP2504015A2 (en) Socs3 inhibition promotes cns neuron regeneration
Wei et al. A novel AAV capsid-mediated RS1 gene therapy restored retinal function to wild-type levels in Rs1R213W mouse model
CN110099999A (zh) 用于听力丧失综合征的动物模型及其治疗方法
Talla et al. Targeted Krüppel-like factor 4 gene knock-out in retinal ganglion cells improves visual function in multiple sclerosis mouse model
WO2023161648A1 (en) Novel use and method comprising il-2 and a tissue- or organ-specific targeting moiety
JP2020059719A (ja) 網膜色素変性症の治療
Kaipa et al. Ocular hypertension impairs axonal transport in the optic nerve head leading to neurodegeneration in a novel Cre-inducible mouse model of myocilin glaucoma
Natali Epigenetics in the adult brain: the role of REST in epilepsy
Rodriguez The Role of Fractalkine-Mediated Neuroprotection in the Diabetic Retina
Cheng et al. Rag1−/− mice with T and B lymphocyte deficiency exhibit milder retinal inflammatory response and retinal ganglion cell injury after optic nerve crush
Henderson Effect of Gene Therapy on Visual Function in Leber's Congenital Amaurosis
Djaksigulova et al. First pilot study of intravenous rAAV-PAX6 gene therapy increases retinal-ganglion-cell-layer thickness and Notch1 transcription in a mouse model of aniridia

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: KATHOLIEKE UNIVERSITEIT LEUVEN

Free format text: FORMER NAME(S): BABRAHAM INSTITUTE; VIB VZW; KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D

Owner name: BABRAHAM INSTITUTE

Free format text: FORMER NAME(S): BABRAHAM INSTITUTE; VIB VZW; KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D

Owner name: VIB VZW

Free format text: FORMER NAME(S): BABRAHAM INSTITUTE; VIB VZW; KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HOLT, MATTHEW; LISTON, ADRIAN; DOOLEY, JAMES; YSHII, LYDIA AND PASCIUTO, EMANUELA